The analysis was made to evaluate the risk of clinical trial failure in advanced NSCLC drug development over the past 14 years. The success rate was thought as the likelihood a new drug would move all phases of clinical trial testing and be approved. Success rates were compared with rates estimated by the biopharmaceutical market as well as rates dependant on risk analysis study in other disease indications. The achievement rate for NSCLC medication development was 11 percent, which is leaner than the market estimate of 16.5 percent. However, success rates were higher for several drug indications; the cumulative success rate was 62 percent for biomarker targeted therapy, which was nearly six moments higher than the price for trials with out a biomarker targeted indication .There may be the case of the eight-year-old African boy diagnosed with Burkitt’s lymphoma at a Ugandan wellness clinic. He was exposed to the measles virus and in the next couple of weeks his tumour regressed completely and he entered remission. But only relatively recently have scientists clinically examined the conversation between infections and cancers in the developing region of oncolytic virotherapy. Associate Professor Darren Shafren of the University of Newcastle provides been looking at the phenomenon for last 15 years. His work is focused on the coxsackie virus, among the causes of the common cold. The beauty using this type of virus is that it episodes cancer cells.